NCT00601900
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Therapeutic Antibody, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior endocrine (hormone) therapy in the metastatic setting; Patients with more than one prior chemotherapy regimen for metastatic disease; Patients with any prior anti-VEGF or VEGFR tyrosine kinase inhibitor therapy; Patients with known central nervous system (CNS) metastases or leptomeningeal disease
https://ClinicalTrials.gov/show/NCT00601900